Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05559164 · ClinicalTrials.gov registry record · Phase 2
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
A Phase 2 study of Early Stage Breast Cancer and Cardiac Toxicity, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 10
- Study locations
NCT05559164: Recruiting Phase 2 study of Early Stage Breast Cancer and Cardiac Toxicity, sponsored by Rutgers, The State University of New Jersey.
NCT05559164 is a Phase 2 study of Early Stage Breast Cancer and Cardiac Toxicity that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 60 participants, below the 411-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (85% lower). The trial reports 10 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05559164, a Phase 2 study of Early Stage Breast Cancer and Cardiac Toxicity, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
Primary Outcome
Adverse events (AEs) will be measured using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 for five years
Conditions Studied
Interventions
- DRUG Lipitor 40mg Tablet
Study Locations (10)
New Jersey
- Trinitas Hospital and Comprehensive Cancer Center - Elizabeth
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton - Hamilton
- RWJBarnabas Health - - Jersey City Medical Medical - Jersey City
- Monmouth Medical Center Southern Campus - Lakewood
- RWJBarnabas Health - Monmouth Medical Center - Long Branch
- Monmouth Community Medical - Long Branch
- Rutgers Cancer Institute of New Jersey - New Brunswick
- RWJBarnabas Health - Robert Wood Johnson University Hospital - New Brunswick
- RWJBarnabas Health - Newark Beth Israel Medical Center - Newark
- RWJBarnabas Health - Robert Wood Johnson University Hospital - Somerset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-09-19 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
What NCT05559164 shows while recruiting
NCT05559164 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 411-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Early Stage Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Lipitor 40mg Tablet is the first listed.
NCT05559164 lists 10 locations in 1 state (New Jersey).
Frequently Asked Questions
What is clinical trial NCT05559164 about?
NCT05559164 is a clinical study titled "Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted". This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
What is the current status of trial NCT05559164?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-09-19. Estimated completion is 2027-03-01.
What conditions does trial NCT05559164 study?
This clinical trial studies the following conditions: Early Stage Breast Cancer, Cardiac Toxicity.
What interventions are being tested in trial NCT05559164?
The interventions under investigation include: Lipitor 40mg Tablet (DRUG).
Who is sponsoring clinical trial NCT05559164?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05559164 being conducted?
This trial has 10 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Stage Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05559164's enrollment target sits among peer trials
60 16th of 21 higher than 6 of 21 other Early Stage Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Stage Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
RECRUITING · Phase 2
-
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
RECRUITING · Phase 2
-
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
RECRUITING · Phase 2
-
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI